Compare
Jasper Therapeutics, Inc. vs Inmune Bio, Inc. vs IN8BIO, Inc. vs Ocugen, Inc.
| Latest fiscal year | Jasper Therapeutics, Inc. JSPR | Inmune Bio, Inc. INMB | IN8BIO, Inc. INAB | Ocugen, Inc. OCGN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $50.0K | n/a | $4.41M |
| Revenue growth (YoY) | n/a | +257.1% | n/a | +8.8% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | n/a | n/m |
| Net margin | n/a | n/m | n/a | n/m |
| Net income | -$75.80M | -$45.93M | -$19.44M | -$67.85M |
| EPS (Diluted) | -$3.95 | -$1.86 | -$4.44 | n/a |
| Operating cash flow | -$77.16M | -$22.58M | -$12.71M | -$56.96M |
| Free cash flow | n/a | -$23.62M | n/a | -$57.15M |
| Cash & equivalents | $28.69M | $24.75M | n/a | n/a |
| Total assets | $35.78M | $32.35M | $32.28M | $43.52M |
| Total liabilities | $31.63M | $8.83M | $4.72M | $55.68M |
| Shareholders' equity | $4.15M | $23.52M | $27.56M | -$12.17M |
| Return on year-end equity | n/m | -195.3% | -70.5% | n/a |
| Shares outstanding | 28.00M | 26.59M | 9.77M | 312.38M |
Revenue, most recent five fiscal years
| Fiscal year | Jasper Therapeutics, Inc. | Inmune Bio, Inc. | IN8BIO, Inc. | Ocugen, Inc. |
|---|---|---|---|---|
| Latest | n/a | $50.0K Ended 2025-12-31 | n/a | $4.41M Ended 2025-12-31 |
| 1 year earlier | n/a | $14.0K Ended 2024-12-31 | n/a | $4.05M Ended 2024-12-31 |
| 2 years earlier | n/a | $155.0K Ended 2023-12-31 | n/a | $6.04M Ended 2023-12-31 |
| 3 years earlier | n/a | $374.0K Ended 2022-12-31 | n/a | $2.49M Ended 2022-12-31 |
| 4 years earlier | n/a | $181.0K Ended 2021-12-31 | n/a | n/a |